TABLE 1.
Study group characteristics
| Subject characteristic | Value for study group |
||||
|---|---|---|---|---|---|
| Multiple myeloma | Waldenstrom's macroglobulinemia | Monoclonal gammopathy of undetermined significance | Control subjects | All | |
| n | 15 | 15 | 15 | 15 | 60 |
| Median age, yrs (range) | 80 (65–88) | 75 (62–88) | 71 (60–77) | 68 (61–83) | 75 (60–88) |
| Female sex, n | 7 | 9 | 9 | 8 | 33 |
| M-protein median, g/liter (range)a | 24 (0.7–44) | 15 (3.0–28) | 11 (0.5–28) | 0 (0–0) | |
| Receiving indicated treatment regimen(s), n | 11 | 1 | 0 | 0 | 12 |
| Melphalan + prednisone | 4 | 0 | 0 | 0 | 4 |
| Cyclophosphamide + dexamethasone | 4 | 0 | 0 | 0 | 4 |
| Pulse steroids | 1 | 0 | 0 | 0 | 1 |
| Thalidomide | 1 | 0 | 0 | 0 | 1 |
| Bortezomib | 1 | 0 | 0 | 0 | 1 |
| Fludarabin | 0 | 1 | 0 | 0 | 1 |
| Receiving ongoing antibiotic treatment, n | 3 | 1 | 0 | 0 | 4 |
| Given pneumococcal vaccine, n | |||||
| PCV7b | 8 | 8 | 7 | 6 | 29 |
| PPV23c | 7 | 7 | 8 | 9 | 31 |
a
Prevaccination levels of monoclonal (M-)protein in serum.
b
PCV7, 7-valent pneumococcal conjugate vaccine.
c
PPV23, 23-valent pneumococcal polysaccharide vaccine.